Wixela Inhub是GSK明星重磅品种Advair Diskus的首个仿制药,在1月30日获批每日2次用于治疗4岁以上哮喘患者以及慢性阻塞性肺病(COPD)患者的气管阻塞。 葛兰素史克Advair全球销售额(百万英镑) Mylan同时公布了3个不同规格Wixela的批发商采购价格(wholesale acquisition cost,WAC并不代表消费者、药房或者第三方支付费机构支...
申请类型 ANDA 申请号 208891 药品名称 WIXELA INHUB 活性成分 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE 活性成分中文 暂无权限 执行时间 2019-02-06 持有公司 MYLAN 说明书 下载 VIP试用医疗器械查询APP下载客服中心常见问题数据可视化数据分析挖掘系统网站地图业务介绍友情链接 400-678-0778 投诉...
All three dosage strengths of Wixela Inhub will be offered at a wholesale acquisition cost of up to 70% less than Advair Diskus and the authorized generic equivalent.doi:10.1007/s40267-019-00686-wHannah A. BlairSpringer NatureDrugs & Therapy Perspectives...
Wixela Inhub and Advair Diskus are comparable in terms of functionality, user interface, and device resistance. The primary objectives of the studies were to evaluate in vitro dose delivery with Wixela Inhub compared with Advair Diskus at relevant flow rates and to explore inhalation profiles ...
2月12日, Mylan 宣布在美国正式上市Wixela Inhub(氟替卡松/沙美特罗),这是GSK重磅品种舒利迭的首个仿制药,用于治疗4岁以上哮喘患者以及慢性阻塞性肺病(COPD)患者的气管阻塞。首仿药价直降70%,降的太厉害, 恒瑞 的还在研发路上,看来是没戏了。
This study aimed at confirming the local (lung) therapeutic equivalence of both the FP and salmeterol components of Wixela Inhub (test [T]) to Advair Diskus (reference [R]) after inhalation. Methods: This randomized, double-blind, double-dummy, placebo-controlled, parallel-group study in ...
Study 2: This is an open-label clinical study to confirm the robustness of the Inhub inhaler after at home patient use. Subjects diagnosed with asthma or COPD were provided Inhub inhaler training and subsequently self-administered 3 weeks of twice daily doses of Wixela Inhub 250 mu g FP/...